Trial Condition(s):
Diabetes Mellitus
GlucoFriend-evaluation the effectiveness of Glucobay when combined with a basal insulin
Bayer Identifier:
15316
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.
Inclusion Criteria
- Signed written informed consent - Age ≥ 18 years - Diagnosed of type 2 diabetes for at least 6 months prior to enrollment - Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months - HbA1C≥7.5 and ≤10.0%
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information
Trial Summary
Enrollment Goal
539
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Acarbose (Precose/Glucobay, BAYG5421)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many Locations, South Korea | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Combined use of a basal insulin and Glucobay For reducing PPG to end diabetes progress
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Change in HbA1cTimeframe: After 20 weeks
Secondary Outcome
- Duration and dose of acarbose treatmentTimeframe: After 20 weeks
- Postprandial Blood GlucoseTimeframe: After 20 weeks
Additional Information
Copyright © Bayer
Powered by
